Difference between revisions of "Essential thrombocythemia"
Jump to navigation
Jump to search
m (→Untreated) |
m (→Untreated) |
||
| Line 18: | Line 18: | ||
|} | |} | ||
| − | ===Regimen #1 | + | ===Regimen #1 {{#subobject:bbeb21|Variant=1}}=== |
| + | {| border="1" style="text-align:center;" !align="left" | ||
| + | |'''Study''' | ||
| + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
| + | |'''Comparator''' | ||
| + | |- | ||
| + | |[http://www.nejm.org/doi/full/10.1056/NEJMoa043800 Harrison et al. 2005 (MRC PT-1)] | ||
| + | |<span | ||
| + | style="background:#00CD00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase III</span> | ||
| + | |[[Essential_thrombocythemia#Aspirin_.26_Hydroxyurea|Aspirin & Hydroxyurea]] | ||
| + | |- | ||
| + | |} | ||
| + | |||
*[[Anagrelide (Agrylin)]] 0.5 mg PO twice daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.") | *[[Anagrelide (Agrylin)]] 0.5 mg PO twice daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.") | ||
*[[Aspirin]] 75 mg (100 mg in Australia) PO once daily | *[[Aspirin]] 75 mg (100 mg in Australia) PO once daily | ||
| − | ===Regimen #2 | + | ===Regimen #2 {{#subobject:abf053|Variant=1}}=== |
| + | {| border="1" style="text-align:center;" !align="left" | ||
| + | |'''Study''' | ||
| + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
| + | |'''Comparator''' | ||
| + | |- | ||
| + | |[http://bloodjournal.hematologylibrary.org/content/121/10/1720.long Gisslinger et al. 2013 (ANAHYDRET)] | ||
| + | |<span | ||
| + | style="background:#00CD00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase III</span> | ||
| + | |[[Essential_thrombocythemia#Aspirin_.26_Hydroxyurea|Hydroxyurea +/- Aspirin]] | ||
| + | |- | ||
| + | |} | ||
| + | |||
*[[Anagrelide (Agrylin)]] 0.5 mg PO twice daily ("increased until maintenance of the platelet count at normal (=450 x 10<sup>9</sup>/L) or close to normal levels (>450 x 10<sup>9</sup>/L to 600 x 10<sup>9</sup>/L)") | *[[Anagrelide (Agrylin)]] 0.5 mg PO twice daily ("increased until maintenance of the platelet count at normal (=450 x 10<sup>9</sup>/L) or close to normal levels (>450 x 10<sup>9</sup>/L to 600 x 10<sup>9</sup>/L)") | ||
*Neither [[aspirin]] nor [[Clopidogrel (Plavix)]] were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion | *Neither [[aspirin]] nor [[Clopidogrel (Plavix)]] were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion | ||
===References=== | ===References=== | ||
| − | # Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [http://www.nejm.org/doi/full/10.1056/NEJMoa043800 | + | # Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [http://www.nejm.org/doi/full/10.1056/NEJMoa043800 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16000354 PubMed] content property of [http://hemonc.org HemOnc.org] |
| + | <!-- Presented in parts in abstract form at the 50th annual meeting of the American Society of Hematology, December 7, 2008. --> | ||
# Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed] | # Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed] | ||
| Line 36: | Line 69: | ||
|} | |} | ||
| − | ===Regimen #1 | + | ===Regimen #1 {{#subobject:d87ecc|Variant=1}}=== |
| + | {| border="1" style="text-align:center;" !align="left" | ||
| + | |'''Study''' | ||
| + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
| + | |'''Comparator''' | ||
| + | |- | ||
| + | |[http://www.nejm.org/doi/full/10.1056/NEJMoa043800 Harrison et al. 2005 (MRC PT-1)] | ||
| + | |<span | ||
| + | style="background:#00CD00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase III</span> | ||
| + | |[[Essential_thrombocythemia#Asprin_.26_Anagrelide|Aspirin & Anagrelide]] | ||
| + | |- | ||
| + | |} | ||
| + | |||
*[[Hydroxyurea (Hydrea)]] 500-1000 mg PO once daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.") | *[[Hydroxyurea (Hydrea)]] 500-1000 mg PO once daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.") | ||
*[[Aspirin]] 75 mg (100 mg in Australia) PO once daily | *[[Aspirin]] 75 mg (100 mg in Australia) PO once daily | ||
| − | ===Regimen #2 | + | ===Regimen #2 {{#subobject:53255b|Variant=1}}=== |
| + | {| border="1" style="text-align:center;" !align="left" | ||
| + | |'''Study''' | ||
| + | |[[Levels_of_Evidence#Evidence|'''Evidence''']] | ||
| + | |'''Comparator''' | ||
| + | |- | ||
| + | |[http://bloodjournal.hematologylibrary.org/content/121/10/1720.long Gisslinger et al. 2013 (ANAHYDRET)] | ||
| + | |<span | ||
| + | style="background:#00CD00; | ||
| + | padding:3px 6px 3px 6px; | ||
| + | border-color:black; | ||
| + | border-width:2px; | ||
| + | border-style:solid;">Phase III</span> | ||
| + | |[[Essential_thrombocythemia#Asprin_.26_Anagrelide|Anagrelide +/- Aspirin]] | ||
| + | |- | ||
| + | |} | ||
| + | |||
*[[Hydroxyurea (Hydrea)]] 1500 mg PO once daily ("increased until maintenance of the platelet count at normal (=450 x 10<sup>9</sup>/L) or close to normal levels (>450 x 10<sup>9</sup>/L to 600 x 10<sup>9</sup>/L)") | *[[Hydroxyurea (Hydrea)]] 1500 mg PO once daily ("increased until maintenance of the platelet count at normal (=450 x 10<sup>9</sup>/L) or close to normal levels (>450 x 10<sup>9</sup>/L to 600 x 10<sup>9</sup>/L)") | ||
*Neither [[aspirin]] nor [[Clopidogrel (Plavix)]] were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion | *Neither [[aspirin]] nor [[Clopidogrel (Plavix)]] were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion | ||
===References=== | ===References=== | ||
| − | # Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [http://www.nejm.org/doi/full/10.1056/NEJMoa043800 | + | # Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. [http://www.nejm.org/doi/full/10.1056/NEJMoa043800 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/16000354 PubMed] |
| + | <!-- Presented in parts in abstract form at the 50th annual meeting of the American Society of Hematology, December 7, 2008. --> | ||
# Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed] | # Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. [http://bloodjournal.hematologylibrary.org/content/121/10/1720.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/23315161 PubMed] | ||
Revision as of 18:50, 22 May 2015
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
8 regimens on this page
9 variants on this page
|
Untreated
Asprin & Anagrelide
| back to top |
Regimen #1
| Study | Evidence | Comparator |
| Harrison et al. 2005 (MRC PT-1) | Phase III | Aspirin & Hydroxyurea |
- Anagrelide (Agrylin) 0.5 mg PO twice daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
- Aspirin 75 mg (100 mg in Australia) PO once daily
Regimen #2
| Study | Evidence | Comparator |
| Gisslinger et al. 2013 (ANAHYDRET) | Phase III | Hydroxyurea +/- Aspirin |
- Anagrelide (Agrylin) 0.5 mg PO twice daily ("increased until maintenance of the platelet count at normal (=450 x 109/L) or close to normal levels (>450 x 109/L to 600 x 109/L)")
- Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion
References
- Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed content property of HemOnc.org
- Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11. link to original article contains verified protocol PubMed
Aspirin & Hydroxyurea
| back to top |
Regimen #1
| Study | Evidence | Comparator |
| Harrison et al. 2005 (MRC PT-1) | Phase III | Aspirin & Anagrelide |
- Hydroxyurea (Hydrea) 500-1000 mg PO once daily ("Doses were subsequently adjusted to maintain the platelet count at less than 400,000 per cubic millimeter.")
- Aspirin 75 mg (100 mg in Australia) PO once daily
Regimen #2
| Study | Evidence | Comparator |
| Gisslinger et al. 2013 (ANAHYDRET) | Phase III | Anagrelide +/- Aspirin |
- Hydroxyurea (Hydrea) 1500 mg PO once daily ("increased until maintenance of the platelet count at normal (=450 x 109/L) or close to normal levels (>450 x 109/L to 600 x 109/L)")
- Neither aspirin nor Clopidogrel (Plavix) were required in the study, but patients who were already taking either drug for at least two weeks were allowed to continue taking it during the study per investigator discretion
References
- Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. link to original article contains verified protocol PubMed
- Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; for all members of the ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. Epub 2013 Jan 11. link to original article contains verified protocol PubMed
Hydroxyurea (Hydrea)
| back to top |
Regimen
| Study | Evidence | Comparator |
| Cortelazzo et al. 1995 | Phase III | Observation |
- Hydroxyurea (Hydrea) 15 mg/kg/day PO
- Doses were subsequently adjusted to maintain the platelet count at less than 600,000 per cubic millimeter without lowering the white-cell count below 4000 per cubic millimeter
References
- Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. link to original article contains verified protocol PubMed
Observation
| back to top |
Regimen
| Study | Evidence | Comparator |
| Cortelazzo et al. 1995 | Phase III | Hydroxyurea |
No active treatment; used as a comparator arm.
References
- Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995 Apr 27;332(17):1132-6. link to original article contains verified protocol PubMed